A dy­nam­ic on­col­o­gy duo team up on an I/O start­up fo­cused on next-gen sol­id tu­mor fight­ers

In the no­to­ri­ous­ly flighty biotech in­dus­try, long­time part­ner­ships aren’t nec­es­sar­i­ly the norm. But a pair of on­col­o­gy vets with a his­to­ry of col­lab­o­ra­tion ap­par­ent­ly likes work­ing to­geth­er just fine — and now they’re kick­start­ing an up­start firm on the hunt against sol­id tu­mors.

Ron­do Ther­a­peu­tics launched Wednes­day with a $67 mil­lion Se­ries A and back­ing from J&J, among oth­ers, to build out its plat­form of next-gen T cell en­gagers and bis­pe­cif­ic an­ti­bod­ies tar­get­ing sol­id tu­mors, the new biotech said in a re­lease.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER